Parenteral Drugs (India) (NSE:PDPL) Forward PE Ratio: 0.00 (As of Jul. 11, 2026)


NSE:PDPL Parenteral Drugs (India) Ltd NSE:PDPL
4 GF Score
Price ₹2.90
View Full Analysis

What is Parenteral Drugs (India) Forward PE Ratio?

Parenteral Drugs (India) NSE:PDPL 4 Forward PE Ratio is 0.00 as of Jul. 11, 2026. GuruFocus rates NSE:PDPL with a GF Score™ of 4/100.

Parenteral Drugs (India)'s Forward PE Ratio for today is 0.00.

Parenteral Drugs (India)'s PE Ratio without NRI for today is 0.00.

Parenteral Drugs (India)'s PE Ratio (TTM) for today is 0.00.

Parenteral Drugs (India)  (NSE:PDPL) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .

Parenteral Drugs (India) Forward PE Ratio Related Terms

Parenteral Drugs (India) Forward PE Ratio Historical Data

* Premium members only.

The historical data trend for Parenteral Drugs (India)'s Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Parenteral Drugs (India) Forward PE Ratio Chart

Parenteral Drugs (India) Annual Data
Trend
Forward PE Ratio

Parenteral Drugs (India) Quarterly Data
Forward PE Ratio

NSE:PDPL vs ZTS, CTLT, VTRS: Forward PE Ratio Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Parenteral Drugs (India)'s Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Parenteral Drugs (India) Forward PE Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Parenteral Drugs (India)'s Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where Parenteral Drugs (India)'s Forward PE Ratio falls into.


NSE:PDPL
4GF Score
Parenteral Drugs (India) Ltd NSE:PDPL
Forward PE Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Parenteral Drugs (India) Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.

Frequently Asked Questions Learn more about Forward PE Ratio →
What does a Forward PE Ratio of 0.00 mean?
Parenteral Drugs (India) (NSE:PDPL) has a Forward PE Ratio of 0.00 as of Jul. 11, 2026. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Parenteral Drugs (India) and its competitors.
Is Parenteral Drugs (India)'s Forward PE Ratio too high?
Parenteral Drugs (India)'s current Forward PE Ratio is 0.00. Overall, Parenteral Drugs (India) has a GF Score™ of 4/100, reflecting its overall financial health beyond just this single metric.
How does Parenteral Drugs (India)'s Forward PE Ratio compare to ZTS and CTLT?
Parenteral Drugs (India)'s Forward PE Ratio of 0.00 can be compared against companies in the Drug Manufacturers industry. The industry median Forward PE Ratio is 17.36. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward PE Ratio for a Drug Manufacturers company?
The median Forward PE Ratio among Drug Manufacturers companies is 17.36, based on 409 companies in the industry. Companies in the top quartile (top 25%) have a Forward PE Ratio significantly above this median, while those in the bottom quartile fall well below. However, Forward PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward PE Ratio mean?
A high Forward PE Ratio can signal that a stock is expensive relative to its fundamentals. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Parenteral Drugs (India) and its competitors. For the Drug Manufacturers industry, the median Forward PE Ratio is 17.36 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Parenteral Drugs (India)'s current Forward PE Ratio is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Parenteral Drugs (India) stock overvalued right now?
Parenteral Drugs (India) (NSE:PDPL) has a current Forward PE Ratio of 0.00. The current Forward PE Ratio is 0.00. Parenteral Drugs (India)'s overall GF Score™ is 4/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward PE Ratio calculated?
Forward PE Ratio is calculated from a company's financial statements. For Parenteral Drugs (India) (NSE:PDPL), the current Forward PE Ratio is 0.00 as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Parenteral Drugs (India) Business Description

Address Navlakha Crossing, A. B. Road, Shree Ganesh Chambers, Indore, MP, IND, 452001
Parenteral Drugs (India) Ltd is a pharmaceutical company. It is principally engaged in manufacturing pharmaceutical preparations. The company manufactures products in categories like intravenous (IV) fluids, oncology, anesthesia, and export products. Its IV fluids products include carbohydrates and electrolytes, diuretics, dialysis, and irrigation solution, anti-infective and anti-fungal, and other pharmaceutical products.
4GF Score

Get the complete analysis for NSE:PDPL

Forward PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹2.90
Price